EHA 2021 | Ruxolitinib plus venetoclax for T-PLL: rationale and findings
Charles Herbaux
• 25 May 2021
Charles Herbaux, MD, MSc, University Hospital of Lille, Lille, France, discusses the use of ruxolitinib in combination with venetoclax as a therapeutic regimen for T-cell prolymphocytic leukemia (T-PLL). Dr Herbaux describes the rationale for the study, which was based on results of BH3 profiling which identified T-PLL cell dependency on BCL-2 and MCL-1 for survival, and gives an overview of the findings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
